World J Clin Cases. Nov 16, 2024; 12(32): 6543-6546 Published online Nov 16, 2024. doi: 10.12998/wjcc.v12.i32.6543
Advanced lung adenocarcinoma with EGFR 19-del mutation transforms into squamous cell carcinoma after EGFR tyrosine kinase inhibitor treatment
Ruo-Bing Qi, Zheng-Hao Wu
Ruo-Bing Qi, Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Zheng-Hao Wu, Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China
Author contributions: Qi RB designed the research study, analyzed the data, and wrote the manuscript; Wu ZH performed the research; Qi RB and Wu ZH contributed new reagents and analytic tools; all authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
Corresponding author: Zheng-Hao Wu, MD, Doctor, Research Associate, Surgeon, Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, Hubei, China.421910799@qq.com
Received: June 19, 2024 Revised: August 2, 2024 Accepted: August 13, 2024 Published online: November 16, 2024 Processing time: 96 Days and 12.5 Hours
Abstract
In this editorial we comment on the article by Ji et al. We focus specifically on the EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment and the development of drug resistance to EGFR-TKIs.
Core Tip: Patients treated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) will inevitably face resistance issues, and resistance to EGFR-TKIs can be divided into two categories: Primary and acquired. Pathological transformation is one of the mechanisms for acquired resistance to EGFR-TKIs, with the transformation to squamous cell carcinoma being relatively rare. This case report provides detailed information on a 67-year-old female patient with advanced lung adenocarcinoma and an EGFR 19del mutation who developed resistance after treatment with EGFR-TKIs.
